SS-31 (elamipretide): mitochondrial peptide research
Understanding SS-31 as an active mitochondrial-targeting research program—not a shortcut to an energy or aging claim.
Educational information only — not medical advice. This page does not diagnose conditions, recommend treatment, or replace care from a qualified clinician. The Peptide Center uses an evidence-first editorial process: regulatory sources, trial registries, and peer-reviewed research take priority; uncertainty is stated rather than filled with promises.
SS-31, also known as elamipretide, is a mitochondria-targeting peptide studied in cardiometabolic and rare-disease research programs. Mitochondrial biology is complex; a compound can affect cellular energetics in a model without producing a meaningful benefit for people outside a trial setting.
References
- Therapeutic peptides: recent advances in discovery, synthesis, and clinical applications. Signal Transduction and Targeted Therapy, 2022
- ClinicalTrials.gov: Learn about studies
- FDA: The drug development process
Related resources
Continue with curated, same-topic resources from the published library. These links are educational references, not treatment recommendations.
Alpha-Klotho mAb
Why a compelling cell or animal result is the beginning of a question, not the end of it.
Open resourcePeptide briefEpithalon
A guide to epithalamin/epithalon aging research without turning telomere biology into a longevity promise.
Open resourcePeptide briefFLGR242
A fast checklist for separating useful research news from overconfident health marketing.
Open resourcePeptide briefFOXO4-DRI
Why a compelling cell or animal result is the beginning of a question, not the end of it.
Open resourcePeptide briefGonadorelin
Why a clinician's off-label discussion is not the same as buying an unapproved product online.
Open resourcePeptide briefKisspeptin
A framework for reviewing a signaling-peptide claim without turning early research into medical guidance.
Open resourceArticlePreparing for a peptide conversation with a clinician
A neutral question list for discussing goals, evidence, product status, and uncertainty.
Open resourceArticleAn adverse-event report is a safety signal, not proof of cause
How to read safety reporting responsibly—and why suspected problems should still be taken seriously.
Open resource